Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer

Journal of Gastrointestinal Cancer

Volumn 40, Issue 3-4, 2009, Pages 119-122

  Miksad, Rebecca A ^a   Lai, Kuan Chi ^a   Stein, Marion C ^a   Healy, Megan E ^a   Rojas, Rafael ^a   Krajewski, Katherine M ^a   Zhu, Andrew X ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SUNITINIB;

AGED; ANAMNESIS; ARTICLE; BALANCE DISORDER; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; GAIT DISORDER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER LOBECTOMY; MALE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SKIN DISCOLORATION; VESTIBULAR DISORDER;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS, PHASE III AS TOPIC; GAIT DISORDERS, NEUROLOGIC; HEPATITIS, AUTOIMMUNE; HUMANS; INDOLES; LIVER NEOPLASMS; MALE; POSTURAL BALANCE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRROLES; SENSATION DISORDERS;

EID: 73549106105     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-009-9086-7     Document Type: Article

References (20)

1. AX Zhu DV Sahani D Duda, et al. 2009 Efficacy, safety and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study J Clin Oncol 27 18 3027 3035 10.1200/JCO.2008.20.9908 1:CAS:528:DC%2BD1MXoslyisb8%3D 19470923
2. DB Mendel AD Laird X Xin, et al. 2003 In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 1 327 337 1:CAS:528:DC%2BD3sXnt1OrtA%3D%3D 12538485
3. TJ Abrams LB Lee LJ Murray NK Pryer JM Cherrington 2003 SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer Molecular cancer therapeutics 2 5 471 478 1:CAS:528:DC%2BD3sXkvVersbw%3D 12748309
4. AM O'Farrell TJ Abrams HA Yuen, et al. 2003 SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo Blood 101 9 3597 3605 10.1182/blood-2002-07-2307 12531805 (Pubitemid 36857948)
5. Sutent Full Prescribing Information. US Food and Drug Administration 2007
6. RJ Motzer TE Hutson P Tomczak, et al. 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2 115 124 10.1056/NEJMoa065044 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D 17215529 (Pubitemid 46089672)
7. G Martin L Bellido JJ Cruz 2007 Reversible posterior leukoencephalopathy syndrome induced by sunitinib J Clin Oncol 25 23 3559 10.1200/JCO.2007.12.8710 17687168 (Pubitemid 47310905)
8. R Cumurciuc L Martinez-Almoyna C Henry H Husson T de Broucker 2008 Posterior reversible encephalopathy syndrome during sunitinib therapy Revue neurologique 164 6-7 605 607 10.1016/j.neurol.2008.03.007 1:STN:280: DC%2BD1czps1Oksw%3D%3D 18565360 (Pubitemid 351893095)
9. R Govindarajan J Adusumilli DL Baxter A El-Khoueiry SI Harik 2006 Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006 J Clin Oncol 24 28 e48 10.1200/JCO.2006.08.4608 17008686
10. J Hinchey C Chaves B Appignani, et al. 1996 A reversible posterior leukoencephalopathy syndrome N Engl J Med 334 8 494 500 10.1056/ NEJM199602223340803 1:STN:280:DyaK287lslSisQ%3D%3D 8559202 (Pubitemid 26067737)
11. B Saito T Nakamaki H Nakashima, et al. 2007 Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia Am J Hematol 82 4 304 306 10.1002/ajh.20772 16947320 (Pubitemid 46564327)
12. AA van der Veldt AJ van den Eertwegh K Hoekman F Barkhof E Boven 2007 Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy Ann Oncol 18 10 1747 1750 10.1093/annonc/mdm455 17890217 (Pubitemid 47506267)
13. S Patyna G Peng 2006 Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intrvenous administration in rodents and monkeys Eur J Cancer 4 12 21
14. AK Koutras D Krikelis N Alexandrou I Starakis HP Kalofonos 2007 Brain metastasis in renal cell cancer responding to sunitinib Anticancer Res 27 6C 4255 4257 1:CAS:528:DC%2BD1cXhtVOmu7o%3D 18214028
15. J Medioni O Cojocarasu JL Belcaceres P Halimi S Oudard 2007 Complete cerebral response with sunitinib for metastatic renal cell carcinoma Ann Oncol 18 7 1282 1283 10.1093/annonc/mdm275 1:STN:280:DC%2BD2svlvVSrsw%3D%3D 17675397 (Pubitemid 47244377)
16. S Negrier 2007 Case Report 3. Sunitinib malate in patients with cerebellar metastases Eur J Cancer Suppl 5 7 32 34 10.1016/S1359-6349(07)70114-3 1:CAS:528:DC%2BD2sXhsVKjsrjP (Pubitemid 350017074)
17. F Thibault B Billemont O Rixe 2008 Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy J Neurooncol 86 2 243 244 10.1007/s11060-007-9449-5 17634858 (Pubitemid 350263426)
18. HH Helgason HA Mallo H Droogendijk, et al. 2008 Brain metastases in patients with renal cell cancer receiving new targeted treatment J Clin Oncol 26 1 152 154 10.1200/JCO.2007.13.5814 18165649
19. D Pouessel S Culine 2008 High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor Eur Urol 53 2 376 381 10.1016/j.eururo.2007.08.053 1:CAS:528:DC%2BD1cXislCnsrg%3D 17825982 (Pubitemid 350296582)
20. ZG Zhang L Zhang Q Jiang, et al. 2000 VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain J Clin Invest 106 7 829 838 10.1172/JCI9369 1:CAS:528:DC%2BD3cXntVyiu7o%3D 11018070